AU741713B2 - Modulation of human mast cell activation - Google Patents

Modulation of human mast cell activation Download PDF

Info

Publication number
AU741713B2
AU741713B2 AU70985/98A AU7098598A AU741713B2 AU 741713 B2 AU741713 B2 AU 741713B2 AU 70985/98 A AU70985/98 A AU 70985/98A AU 7098598 A AU7098598 A AU 7098598A AU 741713 B2 AU741713 B2 AU 741713B2
Authority
AU
Australia
Prior art keywords
purinoceptor
mast cells
agent
atp
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU70985/98A
Other languages
English (en)
Other versions
AU7098598A (en
Inventor
Amir Pelleg
Edward B. Schulman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duska Scientific Co
Original Assignee
AMIR PELLEG DR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AMIR PELLEG DR filed Critical AMIR PELLEG DR
Publication of AU7098598A publication Critical patent/AU7098598A/en
Assigned to SCHULMAN, EDWARD S., Pelleg, Amir Dr. reassignment SCHULMAN, EDWARD S. Alteration of Name(s) of Applicant(s) under S113 Assignors: ALLEGHENY UNIVERSITY OF THE HEALTH SCIENCES
Application granted granted Critical
Publication of AU741713B2 publication Critical patent/AU741713B2/en
Assigned to DUSKA SCIENTIFIC CO. reassignment DUSKA SCIENTIFIC CO. Alteration of Name(s) in Register under S187 Assignors: Pelleg, Amir Dr., SCHULMAN, EDWARD B.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Amplifiers (AREA)
AU70985/98A 1997-03-25 1998-03-24 Modulation of human mast cell activation Ceased AU741713B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4146197P 1997-03-25 1997-03-25
US60/041461 1997-03-25
PCT/US1998/005922 WO1998042353A1 (en) 1997-03-25 1998-03-24 Modulation of human mast cell activation

Publications (2)

Publication Number Publication Date
AU7098598A AU7098598A (en) 1998-10-20
AU741713B2 true AU741713B2 (en) 2001-12-06

Family

ID=21916643

Family Applications (1)

Application Number Title Priority Date Filing Date
AU70985/98A Ceased AU741713B2 (en) 1997-03-25 1998-03-24 Modulation of human mast cell activation

Country Status (9)

Country Link
US (2) US6372724B1 (cg-RX-API-DMAC7.html)
EP (1) EP1011686B9 (cg-RX-API-DMAC7.html)
JP (1) JP2001518118A (cg-RX-API-DMAC7.html)
AT (1) ATE470441T1 (cg-RX-API-DMAC7.html)
AU (1) AU741713B2 (cg-RX-API-DMAC7.html)
CA (1) CA2288821C (cg-RX-API-DMAC7.html)
DE (1) DE69841711D1 (cg-RX-API-DMAC7.html)
DK (1) DK1011686T3 (cg-RX-API-DMAC7.html)
WO (1) WO1998042353A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2288821C (en) * 1997-03-25 2008-10-14 Allegheny University Of The Health Sciences Modulation of human mast cell activation
DK1187617T3 (da) * 1999-06-18 2004-04-13 Alcon Mfg Ltd Fremgangsmåde til at vælge koncentrationen af et amfipatisk antihistaminlægemiddel ved at bestemme lægemidlets overfladeaktivitetsmåltal
GB9916757D0 (en) 1999-07-17 1999-09-15 Glaxo Group Ltd Method
EP1269198A2 (en) * 2000-03-23 2003-01-02 Novartis AG Identification of mast/basophil activation inhibitors
US20040072865A1 (en) * 2001-01-15 2004-04-15 Bouillot Anne Marie Jeanne Aryl piperidine derivatives as inducers of ldl-receptor expression
JP2004520347A (ja) * 2001-01-15 2004-07-08 グラクソ グループ リミテッド Ldl−受容体発現のインデューサーとしてのアリールピペリジンおよびピペラジン誘導体
EP1351937A1 (en) * 2001-01-15 2003-10-15 Glaxo Group Limited Aryl piperidine derivatives as inducers of ldl-receptor expression
MXPA04004215A (es) * 2001-11-06 2004-07-08 Inspire Pharmaceuticals Inc Metodo para el tratamiento o la prevencion de enfermedades inflamatorias.
WO2003070902A2 (en) * 2002-02-20 2003-08-28 Incyte Corporation Receptors and membrane-associated proteins
US20070276126A1 (en) * 2002-08-13 2007-11-29 Incyte Corporation Cell adhesion and extracellular matrix proteins
US20070219353A1 (en) * 2002-09-03 2007-09-20 Incyte Corporation Immune Response Associated Proteins
AU2003279829A1 (en) * 2002-10-04 2004-05-04 Incyte Corp Protein modification and maintenance molecules
AU2003300785A1 (en) * 2002-11-12 2004-06-03 Incyte Corporation Carbohydrate-associated proteins
AU2003295462A1 (en) * 2002-11-13 2004-06-03 Incyte Corporation Lipid-associated proteins
AU2003302234A1 (en) * 2002-11-26 2004-06-18 Incyte Corporation Immune response associated proteins
WO2004098539A2 (en) 2003-04-30 2004-11-18 Incyte Corporation Kinases and phosphatases
WO2006012639A2 (en) * 2004-07-22 2006-02-02 Duska Scientific Co. Method of diagnosing, monitoring and treating pulmonary diseases
EP1910535B1 (en) 2005-06-24 2016-08-17 The Walter And Eliza Hall Institute Of Medical Research Therapeutic pro-apoptotic bh3-like molecules and methods for generating and/or selecting the same
GB0601058D0 (en) * 2006-01-19 2006-03-01 Univ Southampton Mast Cell Carboxypeptidase As A Marker For Anaphylaxis And Mastocytosis
CA2680801A1 (en) * 2007-03-14 2008-09-18 Sierra Molecular Corporation Compositions, systems, and methods for preservation and/or stabilizationof a cell and/or macromolecule
US10517839B2 (en) * 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
US10107795B2 (en) 2012-10-25 2018-10-23 The United States Of America As Represented By The Department Of Veterans Affairs Composition and methods for the prevention and treatment of diet-induced obesity
US10614684B2 (en) 2017-01-31 2020-04-07 The United States Government As Represented By The Treatment of kidney diseases associated with elevated AVP

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733916A (en) * 1995-03-24 1998-03-31 The Trustees Of The University Of Pennsylvania Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53148539A (en) * 1977-05-30 1978-12-25 Fujisawa Pharmaceut Co Ltd Antiallergic agnet
US5158940A (en) * 1990-02-14 1992-10-27 The United States Government As Represented By The Secretary, Dhhs Use of suramin to treat rheumatologic diseases
US5504090A (en) * 1994-03-30 1996-04-02 Trustees Of The University Of Pennsylvania Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury
EP0760850A1 (en) * 1994-05-27 1997-03-12 Glaxo Group Limited P2x RECEPTORS (PURINOCEPTOR FAMILY)
US5874420A (en) 1995-12-26 1999-02-23 Allegheny University Of The Health Sciences Process for regulating vagal tone
CA2288821C (en) * 1997-03-25 2008-10-14 Allegheny University Of The Health Sciences Modulation of human mast cell activation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733916A (en) * 1995-03-24 1998-03-31 The Trustees Of The University Of Pennsylvania Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists

Also Published As

Publication number Publication date
ATE470441T1 (de) 2010-06-15
WO1998042353A1 (en) 1998-10-01
US6465441B2 (en) 2002-10-15
US6372724B1 (en) 2002-04-16
EP1011686B9 (en) 2011-02-09
EP1011686B1 (en) 2010-06-09
JP2001518118A (ja) 2001-10-09
EP1011686A4 (en) 2003-03-19
CA2288821A1 (en) 1998-10-01
AU7098598A (en) 1998-10-20
DE69841711D1 (de) 2010-07-22
DK1011686T3 (da) 2010-10-11
US20020055515A1 (en) 2002-05-09
CA2288821C (en) 2008-10-14
EP1011686A1 (en) 2000-06-28

Similar Documents

Publication Publication Date Title
CA2288821C (en) Modulation of human mast cell activation
Carsetti et al. Different innate and adaptive immune responses to SARS-CoV-2 infection of asymptomatic, mild, and severe cases
Willis et al. Release and actions of prostaglandins in inflammation and fever: inhibition by anti-inflammatory and antipyretic drugs
Partida-Sánchez et al. Innate immunity is regulated by CD38, an ecto-enzyme with ADP-ribosyl cyclase activity
Wilson et al. Adenosine receptors and asthma
Botta Gordon‐Smith et al. Correlation of low CD73 expression on synovial lymphocytes with reduced adenosine generation and higher disease severity in juvenile idiopathic arthritis
Davoine et al. Expression of FcγRIII (CD16) on human peripheral blood eosinophils increases in allergic conditions
Powers et al. Selective inhibition of functional lymphocyte subpopulations by ribavirin
Gabriella Matera et al. New treatments for COPD in the elderly
Frangova et al. BAL neutrophilia in asthmatic patients: a by-product of eosinophil recruitment?
Arm et al. Expression of complement receptors type 1 (CR1) and type 3 (CR3) on circulating granulocytes in experimentally provoked asthma
Boogaerts et al. In vitro modulation of normal and diseased human neutrophil function by pentoxifylline
Okuda et al. Histamine release from human leukocytes by platelet-activating factor
Stosic-Grujicic et al. Down-regulation of experimental allergic encephalomyelitis in DA rats by tiazofurin
Suwaki et al. Modification of eosinophil function by suplatast tosilate (IPD), a novel anti-allergic drug
Gentile et al. The relationship between airway hyperreactivity (AHR) and sodium, potassium adenosine triphosphatase (Na+, K+ ATPase) enzyme inhibition
Bruijnzeel et al. Effects of nedocromil sodium on in vitro induced migration, activation, and mediator release from human granulocytes
Kadioglu et al. Steroid pulse therapy for rheumatoid arthritis: effect on lymphocyte subsets and mononuclear cell adhesion.
Walker Effects of adenosine on guinea pig pulmonary eosinophils
WO1995010287A1 (en) Substituted purine nucleoside analogs and method for treating endotoxin shock
Thomé et al. Nicotine alters the ectonucleotidases activities in lymphocytes: In vitro and in vivo studies
Abrams et al. Cytotoxic T lymphocyte-induced loss of target cell adhesion and lysis involve common and separate signaling pathways.
Fadal The immunobiology and immunopharmacology of the allergic response
DuBuske Introduction: Mediator Assays and Inflammatory Events in Asthma and Allergic Disease:(Immunology Research Institute of New England Symposium)
Lemanske Late-phase pulmonary reactions

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: DR. AMIR PELLEG, EDWARD S. SCHULMAN

Free format text: THE FORMER OWNER WAS: ALLEGHENY UNIVERSITY OF THE HEALTH SCIENCES

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: DUSKA SCIENTIFIC CO.

Free format text: FORMER OWNER WAS: DR. AMIR PELLEG, EDWARD B SCHULMAN